Calidi Biotherapeutics (CLDI) vs 60 Degrees Pharmaceuticals (SXTP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $3.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | SXTP |
|---|---|---|
| Share price | $1.04 | $0.9725 |
| Market cap | $3.82M | $3.42M |
| 1-day change | +2.97% | -11.59% |
| EPS (TTM) | $-36.47 | $-5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $8.62 |
| 52-week low | $0.986 | $0.84 |
| Distance from 52-week high | -96.26% | -88.72% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +280.46% |
| Average volume | 255.53K | 130.52K |
| Shares outstanding | 3.68M | 3.52M |
| Employees | 29 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About 60 Degrees Pharmaceuticals
SXTP stock →60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
CLDI vs SXTP FAQ
Which is bigger, Calidi Biotherapeutics or 60 Degrees Pharmaceuticals?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.82M compared with $3.42M for 60 Degrees Pharmaceuticals (SXTP).
Are Calidi Biotherapeutics and 60 Degrees Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Calidi Biotherapeutics and Biotechnology: Pharmaceutical Preparations for 60 Degrees Pharmaceuticals.